Selected article for: "cell line and leukaemia cell"

Author: Marriott, Andrew S.; Vasieva, Olga; Fang, Yongxiang; Copeland, Nikki A.; McLennan, Alexander G.; Jones, Nigel J.
Title: NUDT2 Disruption Elevates Diadenosine Tetraphosphate (Ap(4)A) and Down-Regulates Immune Response and Cancer Promotion Genes
  • Document date: 2016_5_4
  • ID: 0ozzbp85_3
    Snippet: In order to determine whether transcriptional regulation by Ap 4 A is confined to relatively few genes or is more widespread, we have analysed the transcriptome of a knockout derivative of the KBM-7 chronic myeloid leukaemia (CML) cell line [37] in which the intracellular level of Ap 4 A has been increased 175-fold by disruption of the NUDT2 gene (KBM-7-NuKO, referred to hereafter as NuKO). These cells show profound changes in gene expression com.....
    Document: In order to determine whether transcriptional regulation by Ap 4 A is confined to relatively few genes or is more widespread, we have analysed the transcriptome of a knockout derivative of the KBM-7 chronic myeloid leukaemia (CML) cell line [37] in which the intracellular level of Ap 4 A has been increased 175-fold by disruption of the NUDT2 gene (KBM-7-NuKO, referred to hereafter as NuKO). These cells show profound changes in gene expression compared to the parent KBM-7 cell line with a total of 6288 significantly differentially expressed genes (DEGs) identified. Ingenuity 1 Pathway Analysis was used to highlight the gene networks and metabolic and signaling pathways affected, revealing down-regulation of interferon, inflammatory and innate immune responses and up-regulation of processes involving MHC class II antigens. In addition, many of the most strongly affected genes have roles in promoting cancer metastasis and invasion, suggesting that NUDT2 may offer a novel, pleiotropic target for cancer chemotherapy.

    Search related documents:
    Co phrase search for related documents
    • affect pathway and gene expression: 1
    • affect pathway and immune response: 1, 2, 3
    • cancer chemotherapy and cell line: 1, 2, 3, 4
    • cancer chemotherapy and gene expression: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • cancer chemotherapy and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • cancer chemotherapy and invasion cancer metastasis: 1
    • cancer metastasis and cell line: 1, 2, 3, 4
    • cancer metastasis and gene expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • cancer metastasis and gene network: 1, 2, 3
    • cancer metastasis and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cancer metastasis and invasion cancer metastasis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cancer metastasis and invasion cancer metastasis promote: 1, 2
    • cell line and class II antigen: 1, 2, 3, 4
    • cell line and gene expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell line and gene network: 1, 2, 3
    • cell line and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell line and intracellular level: 1, 2, 3
    • class II antigen and gene expression: 1, 2, 3
    • class II antigen and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23